PMID- 36005109
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220828
IS  - 2310-2861 (Electronic)
IS  - 2310-2861 (Linking)
VI  - 8
IP  - 8
DP  - 2022 Aug 15
TI  - Temperature-Ion-pH Triple Responsive Gellan Gum as In Situ Hydrogel for 
      Long-Acting Cancer Treatment.
LID - 10.3390/gels8080508 [doi]
LID - 508
AB  - BACKGROUND: Promising cancer chemotherapy requires the development of suitable 
      drug delivery systems (DDSs). Previous research has indicated that a hydrogel is 
      a powerful DDS for tumor therapy and holds great potential to offer a feasible 
      method for cancer management. METHODS: In this study, glutathione-gellan gum 
      conjugate (GSH-GG) was synthesized through chemical reaction. Doxorubicin 
      hydrochloride (DOX) was loaded into GSH-GG to accomplish DOX-loaded GSH-GG. The 
      properties, injectability, drug release, and in vitro and in vivo anticancer 
      effects of DOX-loaded GSH-GG were tested. RESULTS: DOX-loaded GSH-GG showed a 
      temperature-ion dual responsive gelling property with good viscosity, strength, 
      and injectability at an optimized gel concentration of 1.5%. In addition, lower 
      drug release was found under acidic conditions, offering beneficial long-acting 
      drug release in the tumor microenvironment. DOX-loaded GSH-GG presented selective 
      action by exerting substantially higher cytotoxicity on cancer cells (4T1) than 
      on normal epithelial cells (L929), signifying the potential of complete 
      inhibition of tumor progression, without affecting the health quality of the 
      subjects. CONCLUSIONS: GSH-GG can be applied as a responsive gelling material for 
      delivering DOX for promising cancer therapy.
FAU - Zhou, Shuwen
AU  - Zhou S
AUID- ORCID: 0000-0002-1231-4088
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China.
AD  - The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 
      Changzhou 213003, China.
FAU - Zheng, Xinmeng
AU  - Zheng X
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China.
FAU - Yi, Ke
AU  - Yi K
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China.
FAU - Du, Xuancheng
AU  - Du X
AD  - School of Physics, Shandong University, Jinan 250100, China.
FAU - Wang, Cheng
AU  - Wang C
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China.
AD  - The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 
      Changzhou 213003, China.
FAU - Cui, Pengfei
AU  - Cui P
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China.
AD  - The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 
      Changzhou 213003, China.
FAU - Jiang, Pengju
AU  - Jiang P
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China.
FAU - Ni, Xinye
AU  - Ni X
AD  - The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, 
      Changzhou 213003, China.
FAU - Qiu, Lin
AU  - Qiu L
AUID- ORCID: 0000-0002-6514-6006
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China.
FAU - Wang, Jianhao
AU  - Wang J
AUID- ORCID: 0000-0003-3133-6132
AD  - School of Pharmacy, Changzhou University, Changzhou 213164, China.
LA  - eng
GR  - KJS2104/Project of Jiangsu Province Key Laboratory of Radiation Medicine and 
      Protection, Soochow University/
GR  - CJ20210142/Science &Technology Support Program of Changzhou/
GR  - 21KJD350003/Scientific Research Foundation of Jiangsu Provincial Education 
      Department, China/
PT  - Journal Article
DEP - 20220815
PL  - Switzerland
TA  - Gels
JT  - Gels (Basel, Switzerland)
JID - 101696925
PMC - PMC9407511
OTO - NOTNLM
OT  - cancer
OT  - doxorubicin
OT  - gellan gum
OT  - hydrogel
OT  - responsive
COIS- The authors declare no conflict of interest.
EDAT- 2022/08/26 06:00
MHDA- 2022/08/26 06:01
PMCR- 2022/08/15
CRDT- 2022/08/25 07:32
PHST- 2022/06/20 00:00 [received]
PHST- 2022/08/03 00:00 [revised]
PHST- 2022/08/05 00:00 [accepted]
PHST- 2022/08/25 07:32 [entrez]
PHST- 2022/08/26 06:00 [pubmed]
PHST- 2022/08/26 06:01 [medline]
PHST- 2022/08/15 00:00 [pmc-release]
AID - gels8080508 [pii]
AID - gels-08-00508 [pii]
AID - 10.3390/gels8080508 [doi]
PST - epublish
SO  - Gels. 2022 Aug 15;8(8):508. doi: 10.3390/gels8080508.